Beactica is a drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. We offer expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using our proprietary Sprint™ platform.

Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR biosensor-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes.

Latest News


Upcoming events

31 May - 8 June, 2014, Beactica's CSO will present at the 47th crystallographics course ("Structural Basis of Pharmacology: Deeper Understanding of Drug Discovery through Crystallograpy") in Erice, Italy.
23-25 April, 2014, Beactica's CSO will present at Cambridge Healthtech Institute's Ninth Annual Drug Discovery Chemistry conference in San Diego, USA. The preliminary title is "Fragment-Based Discovery of KDM Inhibitors".